Abstract:Objective: To discuss relevant issues in the diagnosis of mental disorders comorbid with fetal alcohol spectrum disorders (FASD). Methods: We present a theoretical model of the effect of prenatal alcohol exposure on neurobehavioral development and a systematic review of published data on the mental disorders in subjects with an FASD. Results: Prenatal alcohol exposure is associated with high rates of mental disorders. We found 48 papers reporting on 3,343 subjects. The most common mental disorder comorbid with… Show more
“…Numerous studies have found individuals with FASDs to be at elevated risk for disruptive behavior problems, mood disorders, substance use or abuse problems, and psychiatric confinement [Famy et al, 1998;O'Connor et al, 2002;Burd et al, 2003;Streissguth et al, 2004;Bhatara et al, 2006;Burd et al, 2007;Walthall et al, 2008]. Given such findings, it is not surprising that children with FASDs often receive pharmacological intervention.…”
Exposure to alcohol in utero is considered to be the leading cause of developmental disabilities of known etiology. The most severe consequence of such exposure, fetal alcohol syndrome (FAS), is characterized by a distinct constellation of characteristic facial anomalies, growth retardation, and central nervous system (CNS) dysfunction. Some individuals with prenatal alcohol exposure (PAE) do not meet the full criteria for FAS, but instead are diagnosed with partial FAS, alcohol related neurodevelopmental disorder (ARND), or alcohol related birth defects (ARBD). The entire continuum of effects from PAE is increasingly being referred to under the umbrella term of fetal alcohol spectrum disorders (FASDs). An extensive body of research has documented major cognitive, behavioral, adaptive, social, and emotional impairments among individuals with FASDs. Although FAS was identified in the U.S. over 35 years ago, the development, evaluation, and dissemination of evidencebased interventions for individuals with FASDs have lagged behind significantly. Encouragingly, however, in recent years there has been a marked increase in efforts to design and test interventions to remediate the impairments associated with prenatal alcohol exposure. This article will review treatment needs and considerations for individuals with FASDs and their families, current empirically tested treatment approaches, case management issues, and suggestions for future directions in research on the treatment of FASDs. ' 2009 Wiley-Liss, Inc. Dev Disabil Res Rev 200915:258-267.
“…Numerous studies have found individuals with FASDs to be at elevated risk for disruptive behavior problems, mood disorders, substance use or abuse problems, and psychiatric confinement [Famy et al, 1998;O'Connor et al, 2002;Burd et al, 2003;Streissguth et al, 2004;Bhatara et al, 2006;Burd et al, 2007;Walthall et al, 2008]. Given such findings, it is not surprising that children with FASDs often receive pharmacological intervention.…”
Exposure to alcohol in utero is considered to be the leading cause of developmental disabilities of known etiology. The most severe consequence of such exposure, fetal alcohol syndrome (FAS), is characterized by a distinct constellation of characteristic facial anomalies, growth retardation, and central nervous system (CNS) dysfunction. Some individuals with prenatal alcohol exposure (PAE) do not meet the full criteria for FAS, but instead are diagnosed with partial FAS, alcohol related neurodevelopmental disorder (ARND), or alcohol related birth defects (ARBD). The entire continuum of effects from PAE is increasingly being referred to under the umbrella term of fetal alcohol spectrum disorders (FASDs). An extensive body of research has documented major cognitive, behavioral, adaptive, social, and emotional impairments among individuals with FASDs. Although FAS was identified in the U.S. over 35 years ago, the development, evaluation, and dissemination of evidencebased interventions for individuals with FASDs have lagged behind significantly. Encouragingly, however, in recent years there has been a marked increase in efforts to design and test interventions to remediate the impairments associated with prenatal alcohol exposure. This article will review treatment needs and considerations for individuals with FASDs and their families, current empirically tested treatment approaches, case management issues, and suggestions for future directions in research on the treatment of FASDs. ' 2009 Wiley-Liss, Inc. Dev Disabil Res Rev 200915:258-267.
“…FASD may be as prevalent as 1% of live births and the affected person has increased risk for a wide range of mental disorders and social impairments that differ over the lifespan (Burd et al, 2007a;Sampson et al, 1997;Streissguth et al, 2004). The disorder is recurrent and the incidence of the disorder among siblings of those diagnosed with fetal alcohol syndrome (FAS) ranges from 170 per 1,000 for older siblings to 771 per 1,000 for younger siblings, making FASD both one of the most recurrent and most preventable developmental disorders (Abel, 1988).…”
Section: Introductionmentioning
confidence: 99%
“…Early detection of infants with prenatal alcohol exposure (PAE) combined with close monitoring of developmental progress may provide early access to intervention during an optimal time period to maximize developmental potential (Burd, 2006). Early diagnosis and intervention may also have an important role in prevention of secondary disabilities (Burd et al, 2007a;Streissguth et al, 2004). Mothers of a child diagnosed with an FASD are in urgent need of substance abuse treatment to prevent recurrence of FASD in subsequent pregnancies.…”
The accurate identification of alcohol-exposed pregnancies represents a significant challenge in the development of FAEE detection cutoffs to maximize the sensitivity and specificity of the test. We present several options for the improvement of exposure assessment in future studies of FAEE as biomarkers for PAE.
“…Although attention deficits among children with FASDs are well documented in the literature and corroborate the widespread presence of these problems in children with PAE [39][40][41], investigators have suggested that while they may share common features, the inattention and hyperactivity associated with PAE denote a particular clinical subtype with an earlier onset, a different clinical and neuropsychological presentation, and probably a differential medication response than idiopathic ADHD [3•, 39, 42]. Significantly, results reported from three large population-based pregnancy offspring cohorts within the Nordic Network on ADHD found that PAE was not related to risk for ADHD after adjustment for covariates [43].…”
Overwhelming evidence on the impact of maternal alcohol consumption during pregnancy has prompted increased attention to the link between prenatal alcohol exposure (PAE) and a constellation of developmental disabilities, which are characterized by physical, cognitive, and behavioral impairments. Importantly, individuals with PAE are particularly vulnerable to mental health problems. This review summarizes the current literature on the underlying mechanisms of PAE vulnerability, including epigenetic, genetic, and environmental risk factors that predispose individuals with PAE to psychiatric illness. The studies cited are from animal and human research and include a developmental perspective. Research on the mental health problems suffered by individuals with fetal alcohol spectrum disorders (FASDs) throughout development highlights the need for training of mental health professionals in the identification and the provision of specific treatments to address the unique features of this developmental disability.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.